Faculty:  Dixie Harms, DNP, ARNP, FNP-C, BC-ADM, FAANP and Patricia Overton-Keary, MD

Review the latest clinical guidelines, the rationale for early intensive glycemic control, and available pharmacologic therapies currently available to you and your patients. The goal of this course is to help you select the best therapeutic options on the basis of the most recent evidence-based guidelines.

Please review this page completely before starting this course. Links to the course options can be found at the bottom of this page.

• Explain why early intensive insulin therapy may be advantageous for patients with diabetes

• Implement evidence-based management strategies to achieve glycemic control in patients with type 2 diabetes

MEBN's mission is to provide medical education that is accurate, fair-balanced, unbiased and evidence-based. MEBN strives to ensure that every educational activity maintains independence, objectivity and scientific rigor. All faculty participating in these activities are expected to disclose any (or no) relevant financial interest or other relationship with (1) the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in any educational presentation, and/or (2) with any commercial supporters of an activity. Disclosure of these relationship(s) will be listed prior to any educational activity.

All apparent conflicts of interest have been identified and resolved through MEBN’s independent, peer-review process. Our intent is to assist learners in assessing the potential for bias in information that is presented during the educational activity. The faculty are also aware of their responsibility to inform the audience if discussion of any non-FDA-approved uses of pharmaceuticals, medical equipment, prostheses, etc. will be included in their presentation. Unless otherwise indicated, MEBN staff and writers have no financial relationships with a commercial party to disclose.

Unless otherwise indicated, MEBN staff and writers have no financial relationships with a commercial party to disclose.

This continuing education program may contain discussion of published and/or investigational uses of agents or products that are not approved by the Food and Drug Administration (FDA). The authors, sponsors or publishers do not recommend the use of any agent or product outside of the official labeled indications. Please refer to the official prescribing information for each agent or product for discussion of approved indications, contraindications, and written warnings.

Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this course should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The authors, contributors, and editorial staff have made every effort to contact holders of copyright to obtain permission to reproduce copyright material. However, if any permissions have been inadvertently overlooked, MEBN will be pleased to make the necessary and reasonable arrangements.